# 1 **Optimal age targeting for pneumococcal vaccination in older adults; a**

# 2 **modelling study.**

3

## 4 **Authors:**

- 5 Deus Thindwa, MSc  $^{1,2,3}$ , Samuel Clifford, PhD  $^{1,2}$ , Jackie Kleynhans, MSc  $^{4,5}$ , Prof Anne von
- 6 Gottberg, PhD<sup>4,6</sup>, Sibongile Walaza, PhD<sup>4</sup>, Susan Meiring, MBChB<sup>4</sup>, Todd D Swarthout, PhD
- $3^{3,7}$ , Prof Elizabeth Miller, FMedSci<sup>2</sup>, Prof Peter McIntyre, D Med Sc<sup>9</sup>, Prof Nick Andrews, PhD
- 8 <sup>8</sup>, Zahin Amin-Chowdhury, PhD<sup>8</sup>, Norman Fry, PhD<sup>8</sup>, Kondwani Jambo, PhD<sup>3,10</sup>, Prof Neil
- 9 French, PhD  $3,11$ , Samanta Cristine Grassi Almeida, PhD  $12$ , Prof Shamez Ladhani, PhD  $8$ , Prof
- 10 Robert S Heyderman, PhD  $^{3,7}$ , Prof Cheryl Cohen, PhD  $^{4,5}$ , Prof Maria Cristina de Cunto

```
11 Brandileone, PhD ^{12}, Prof Stefan Flasche, PhD ^{1,2}.
```
12

# 13 **Institutions:**

- $14$   $^{-1}$  Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene  $\&$
- 15 Tropical Medicine, London, UK
- $16<sup>2</sup>$  Department of Infectious Disease Epidemiology London School of Hygiene & Tropical

17 Medicine, London, UK

- <sup>3</sup> 18 Malawi Liverpool Wellcome Research Programme, Blantyre, Malawi
- <sup>4</sup> Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases
- 20 of the National Health Laboratory Service, Johannesburg, South Africa
- $21<sup>5</sup>$  School of Public Health, University of the Witwatersrand, Johannesburg, South Africa
- <sup>6</sup> School of Pathology, University of the Witwatersrand, Johannesburg, South Africa
- 7 23 Division of Infection and Immunity, University College London, London, UK

- <sup>8</sup> 24 Immunisation and Countermeasures Division, UK Health Security Agency, London, UK
- 25 <sup>9</sup> University of Otago, Dunedin, New Zealand
- <sup>10</sup> Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK.
- $11<sup>11</sup>$  Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, UK
- 28 <sup>12</sup> National Laboratory for Meningitis and Pneumococcal Infections, Laboratory for Meningitis,
- 29 Pneumonia and Pneumococcal Infection, Centre of Bacteriology, Brazil
- 30

# 31 **Corresponding author:**

- 32 \*Email:deus.thindwa@lshtm.ac.uk
- 33 Phone: +265997788370
- 34 Malawi Liverpool Wellcome Research Programme, Blantyre, Malawi & Department of
- 35 Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, Keppel
- 36 Street, London, UK
- 37

# 38 **Abstract**

### 39 **Background**

- 40 Invasive pneumococcal disease (IPD) risk increases with age for older adults whereas the
- 41 population size benefiting from pneumococcal vaccines and the robustness of the immunogenic
- 42 response to vaccination decline. This poses a conundrum for identifying the optimal age for
- 43 vaccination. We estimate how demographics, vaccine efficacy/effectiveness (VE), and waning
- 44 VE impact on optimal age for single-dose pneumococcal vaccination.

45

#### 46 **Methods**

47 Age- and vaccine-serotype-stratified IPD incidence from routine surveillance of adults ≥55 years

48 old (y) in Brazil, England, Blantyre (Malawi), and South Africa,  $\geq$ 4-years after infant-

- 49 pneumococcal vaccine introduction and before 2020, was used to parameterise exponential
- 50 growth models of increasing IPD risk with age. A piecewise-constant model estimated VE and
- 51 waning VE from prior studies. All estimates were then combined in a cohort model to assess the
- 52 vaccine preventable IPD burden of delivering 13-, 15-, 20-valent conjugate or 23-valent

53 polysaccharide vaccines at various ages.

54

### 55 **Findings**

56 In Brazil, Malawi, South Africa and England 51%, 51%, 54% and 39% of adults older than 55y

57 were younger than 65y old. A smaller share of IPD was reported among adults <65y old in

- 58 England (4,657 annual cases; 20% <65y) compared to Brazil (186; 45%), Malawi (4; 63%), or
- 59 South Africa (134, 48%). PCV13- and PPV23-serotypes were estimated to cause 39% and 85%
- 60 of IPD cases on average across settings. Vaccination at 55y in Brazil, Malawi, and South Africa,



### 75 **Research in context**

#### 76 Evidence before this study

77 A recent review conducted for the World Health Organisation (WHO) Scientific Advisory Group 78 of Experts (SAGE) working group on pneumococcal vaccines reviewed the evidence on the 79 efficacy, effectiveness and potential impact of pneumococcal vaccines in older adults. At the 80 time, little evidence was identified to support recommendations for the age of pneumococcal 81 vaccination in older adults, particularly in LMICs. We did an updated search of PubMed, 82 Medline, Embase and Web of Science for studies on age targeting for pneumococcal vaccination 83 in older adults published from Jan 1, 2003 to June 30, 2022, using the search terms "(optimal age 84 targeting OR age targeting OR timeliness) AND (pneumococcal vaccination OR pneumococcal 85 vaccines) AND (adults OR older adults OR elderly)". We identified one study on the role of 86 timeliness in the cost-effectiveness of older adult vaccination in Australia. This study explored 87 the impact of the timeliness of pneumococcal conjugate vaccination (PCV) in older adults and 88 found that more hospitalisations and deaths can be prevented if PCV13 was given to 70y old than 89 as recommended at 65y. On the other hand, most low-income countries (LICs) and middle-90 income countries (MICs) do not have routine older adult pneumococcal vaccination programmes, 91 despite often less indirect protection from childhood PCV programmes and high burden of 92 vaccine preventable disease. The implications of differences in population demographics and risk 93 for IPD compared to high income countries on the optimal age for pneumococcal vaccination in 94 LICs/MICs are unknown.

95

96 Added value of this study



115 programmes will also need to be considered.

# 117 **Introduction**

118 *Streptococcus pneumoniae* (pneumococcus) is a major global cause of childhood mortality [1,2], 119 but also causes a high burden of disease among older adults [2,3]. Two vaccines have been used 120 to prevent pneumococcal disease in older adults ≥55 years-old (y): a 13-valent pneumococcal 121 conjugate vaccine (PCV13) and a 23-valent pneumococcal polysaccharide vaccine (PPV23) [4]. 122 Recently, 15- and 20-valent PCVs (PCV15, PCV20) have also been licensed and recommended 123 for older adults in the United States [5,6]. 124 125 Although routine infant PCV programmes have generated indirect protection against vaccine-126 serotype (VT) pneumococcal disease among older adults [7,8], a substantial disease burden 127 remains, composed of serotypes not targeted by childhood PCV programmes and residual 128 circulation of VT [2,9]. Among high-income countries (HICs) with a mature infant-PCV13 129 programme, PCV13- and PPV23-targeted serotypes caused about 15% and 42%, respectively, of 130 invasive pneumococcal disease (IPD) in older adults [2,10]. Routine infant-PCV programmes in 131 many low- and middle-income countries (LICs and MICs) have often led to less pronounced 132 herd effects with continued circulation of VTs especially in the unvaccinated adult population 133 [11,12], who happen to have no access to routine pneumococcal vaccination [13]. 134 135 The recommended age for pneumococcal vaccination in older adults in HICs is typically either at 136 60y or 65y [4,14]. However, yet only a single study has assessed the age at which the most gain

137 from such programme is seen (in the Australian context) [15]. As the risk of severe

138 pneumococcal disease increases with age [10,15], waning of protection from vaccination early in

139 older adulthood risks disease at ages of highest disease incidence, whereas vaccination late in

- 140 older adulthood cannot address the substantial disease burden among a large pool of susceptible 141 older adults who have not yet been vaccinated.
- 142

143 In this modelling study, we explore the optimal age-targeting for a single-dose pneumococcal

144 vaccination against VT-IPD in older adults living without human immunodeficiency virus (HIV)

- 145 in Brazil, England, Malawi, and South Africa.
- 146

# 147 **Methods**

# 148 **Study sites**

149 We included England (HIC), Brazil and South Africa (MICs), and Blantyre in Malawi (LIC) in 150 this analysis, to explore the optimal age-targeting for pneumococcal vaccination, as all have 151 long-standing adult pneumococcal surveillance programmes at the national or sub-national level 152 [9,16–18]. More details on the respective IPD surveillance systems are in the appendix (Text 153 S1). Infant-PCV13 has been in use since 2011 in South Africa (two primary doses and booster 154 (2+1) schedule) and Malawi (3+0 schedule), with estimated 90-95% vaccination coverage 155 [11,18]. In England, routine PCV13 immunisation programme with 92% booster dose coverage 156 has been in place since 2010, initially using a 2+1 schedule, switching to 1+1 schedule in 2020 157 [19]. In Brazil, a routine infant-PCV10 programme was implemented in 2010 with a 3+1 158 schedule, switched to a 2+1 in 2016, with average coverage of 94% between 2015 and 2017 [20]. 159 160 In England, PPV23 has been recommended for risk groups since 1992, and for all adults aged <sup>161</sup>≥65y since 2003, with single-dose coverage rising to 70% in 2018 [17,21]. In Brazil, PPV23 is

162 not included in the national immunisation programme but has been recommended for use since

163 the 1980s, and is available free of charge at the centers of special immunobiological for people 164 above 2 years old including institutionalised older adult, and thus coverage of <1% among all 165 older adults above 60y [22]. In South Africa, although adult pneumococcal vaccination is 166 recommended, there is no routine programme nor nationally accepted guidelines [23]. In 167 Malawi, neither routine adult pneumococcal vaccination programme nor national guidelines exist 168 [13].

169

# 170 **Population demographics**

171 The population demographics for adults ≥55y were obtained in annual age strata from population

172 censuses conducted in 2010 for Brazil [24], 2011 England (updated in 2017) [25], 2018 Malawi

173 [26], and 2011 South Africa [27]. To align with IPD surveillance timelines in respective

174 countries, annual age population censuses were projected at a constant growth rate of 0·8%

175 during 2010-2016 in Brazil and 1·3% during 2011-2016 in South Africa [28,29]. For England

176 and Malawi, 2017 and 2018 populations already aligned with IPD surveillance time. Annual age

177 population estimates were smoothed to reduce demographic stochasticity in downstream results

178 by applying a 5-year moving average [30].

179

#### 180 **Invasive pneumococcal disease burden**

181 For each site we used data on IPD burden in older adults in the presence of a mature infant-PCV

182 programme, defined as at least 4 years after infant-PCV introduction, to avoid inclusion of

183 ongoing changes in IPD burden attributable to indirect effects from the childhood programme

184 [31]. The number of IPD cases caused by all serotypes, and serotypes targeted by PCV13,

185 PCV15, PCV20 and PPV23 in annual age strata (55y to 85y+) were obtained from laboratory-

186 based surveillance in each country (Fig S1). We calculated age and serotype distribution and 187 proportionally inflated estimates by the number of IPD cases without serotyping available to 188 correct for proportion serotyped. In England, where PPV23 has been in use in 65y+ at 70% 189 uptake, we back-inflated the number of IPD cases in order to correct for the fact that in the 190 absence of PPV23 vaccination, IPD incidence would be higher, especially in ages eligible for 191 PPV23 vaccination. Details about back-inflation calculation are in the appendix (Text S2). Age 192 aggregated (55-59y, 60-64y, 65-69y, 70-74y, 75-79y, 80-84y and 85y+) and serotype-specific 193 IPD incidence was calculated by dividing by the age-group specific population estimates. Due to 194 the small number of reported IPD cases and incomplete serotyping information in Malawi, we 195 only calculated the serotype distribution for all cases and assumed that it was the same in each 196 age group. 197

198 The focus of this study was vaccination strategies for older adults living without HIV because 199 adults living with HIV often have independent pneumococcal vaccine recommendations [12]. 200 Thus, for adult HIV prevalence of >10% in South Africa [32], we adjusted IPD incidence 201 estimates for HIV status. For 201 (18·7%) reported IPD cases, HIV status was reported. We took 202 a 30% random subset of IPD cases with known HIV status and estimated a 49.3% proportion of 203 IPD cases without HIV for this subset. We assumed that a similar proportion of IPD cases with 204 unknown HIV status would be without HIV. We further accounted for similar serotype 205 distribution in those with and without HIV. In Malawi, IPD cases could not be stratified by HIV 206 infection status, and thus we used the age-dependent HIV infection rates in the general adult 207 population and applied the relative propensity for IPD in older adults with and without HIV from 208 South Africa to infer the incidence of IPD among older adults without HIV by age.



231



241

### 242 **PCV and PPV vaccine impact model**

243 We developed a cohort model to simulate the risk for IPD in adults >55y in all four countries. 244 Time steps in the model were set at 1 year. Age-dependent all-cause mortality was set to match 245 observed population demographics of older adults living without HIV in all countries, and age-246 dependent IPD risks were set to match fitted IPD incidence in respective countries and years. We 247 calculated the vaccine preventable number of IPD cases as the lifetime number of cases averted 248 through vaccinating 100% of adults at the specified age for vaccination under the scenarios of 249 age-dependency on initial VE and waning VE. We estimated the efficiency of the alternative 250 strategies by reporting the number of age cohort individuals needed to vaccinate (or number of 251 doses needed to administer to age cohort) in order to prevent a case.

- 253 Sensitivity analysis assessed the influence of age-dependent initial VE on vaccine impact. All
- 254 analyses were conducted using R language v4·1·1, with data and code available through GitHub
- 255 https://github.com/deusthindwa/optimal.age.targeting.pneumo.vaccines.
- 256

### 257 **Ethical approval**

- 258 In Brazil, no patient consent is required since data are obtained through the National
- 259 Epidemiological Surveillance approved by the Scientific Committee of the Instituto Adolfo Luiz
- 260 (CTC 61-M/2020). In England, the UK Health Security Agency (UKHSA) has legal permission,
- 261 provided by Regulation 3 of The Health Service Regulations 2002, to monitor the safety and
- 262 effectiveness of vaccines for national surveillance of communicable diseases
- 263 (http://www.legislation.gov.uk/uksi/2002/1438/regulation/3/made). In Malawi, the study
- 264 protocol was approved by Malawi's National Health Sciences Research Committee (protocol
- 265 867), Kamuzu University of Health Sciences College of Medicine Research Ethics Committee
- 266 (COMREC) (P·01/08/609 and P·09/09/826), and the University of Liverpool Research Ethics
- 267 Committee (RETH490). Individual patient informed consent was not required for the use of
- 268 publicly available anonymised routine samples as per COMREC guidelines 5·6. In South Africa,
- 269 ethical approval to conduct laboratory-based and enhanced surveillance was obtained from the
- 270 Health Research Ethics Committee (Human), University of Witwatersrand (M140159) and
- 271 individual patient consent was obtained for clinical data collection at enhanced surveillance sites.
- 272 Ethical approval for this study was granted by the London School of Hygiene and Tropical

273 Medicine (25787).

274

### 275 **Results**

# 276 **Population demographics and IPD burden**

- 277 Of the 27·7 million (m) older adults  $(\geq 55y)$  in Brazil, 16.5m in England, 66,589 in Blantyre
- 278 Malawi, and 6·9m in South Africa, the proportion of older adults aged 55y to <65y was 51·3%,
- 279 51·0% and 53·8% in Brazil, Malawi and South Africa, substantially higher than the 39·1% in
- 280 England. During the study period, Brazil (2015-2017), England (2016-2019), Malawi (2016-
- 281 2019) and South Africa (2015-2018) reported 559, 13,971, 19, 537 IPD cases in adults ≥55y
- 282 equivalent to an average annual number of cases of 186·3, 4,658·0, 4·8 and 134·3, respectively.
- 283 Of these in the ≥55y, 44·5%, 19·9%, 62·5%, and 47·9% were in <65y olds. Cases caused by
- 284 PCV13 serotypes accounted for 61·4% (343/559), 21·0% (2,936/13,971), 41·0% (8/19), and
- 285 32·8% (176/537) of all IPD in Brazil, England, Malawi and South Africa, and PPV23 serotypes

286 for 97·9% (547/559), 72·5% (10,126/13,971), 94·8% (18/19), and 73·2% (393/537), respectively

287 (Fig 1).

288

289 The exponential model fitted the increase in IPD incidence with age well. The estimated IPD

290 incidence in 85y was higher than in 55y olds by 2·48-fold (95% confidence interval [95%CI]:

291 2·13-2·83) in Brazil, 2·19-fold (95% CI: 0·14-4·51) in Malawi, and 2·25-fold (95% CI: 1·88-

292 2·62) in South Africa. In England the incidence increased more steeply to 11·00-fold (95% CI:

293 10·90-11·40) higher in 85y than 55y (Fig 1).

294

295 While the estimated number of IPD cases declined with age in Brazil, Malawi and South Africa,

296 it increased in England. On the other hand, age-specific IPD incidence of total IPD incidence

297 (age-scaled IPD incidence) increased with age in all settings irrespective of serotype, and with

298 high uncertainty in Malawi due to small case numbers (Fig S4, Fig S5).

**(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2022.11.07.22282045;](https://doi.org/10.1101/2022.11.07.22282045) this version posted November 8, 2022. The copyright holder for this preprint





300 Figure 1. Population demographics and invasive pneumococcal disease (IPD) burden. (Left 301 panel) Among individuals who are aged  $\geq$ 55y, the proportion/share in annual age groups in 302 Brazil, England, Malawi and South Africa as estimated from their national censuses, based on 303 five years rolling average smoothed population counts to control for demographic stochasticity; 304 (Middle panel) Number of IPD cases in five year age bands in older adults stratified by serotype 305 in Brazil (2015-2017), England (2016-2019), Blantyre Malawi (2016-2019) and South Africa 306 (2015-2018), reported from at least four years post-infant PCV introduction in each country. 307 (Right panel) Serotype-specific reported and predicted IPD incidence per 100,000 population 308 between 55y and 90y in Brazil, England, Malawi and South Africa. The black circle represents 309 estimated IPD cases per 100,000 population, the vertical line through the circle represents a 95% 310 uncertainty interval in estimated IPD case number, the curve line is the exponential model fit and 311 the ribbon represents a bootstrapped 95% confidence interval for the fitted line. The red and % nd It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

312 black points for England represent estimated IPD cases in the presence and absence of PPV23 313 vaccination, respectively.

314

### 315 **Optimal age for vaccination**

316 The optimal age for vaccination, the age of a single-dose vaccination that could prevent most

317 IPD cases, is attained when vaccines are given earlier in the considered age range in the

318 LIC/MIC setting, but not for England (Fig 2). In the base scenario with rapid waning of PPV23

319 VE, we found that the highest proportion of all IPD cases could be preventable if adults aged 55y

320 are vaccinated in Brazil (30·5%, 22·4-43·3), in Malawi (31·0%, 7·7-96·6), and in South Africa

321 (20·0%, 13·7-28·7), and if adults aged 70y are vaccinated in England (13·7%, 10·8-17·4)

322 compared to a scenario without vaccination (Table S1). Also, In the base scenario with rapid

323 waning VE, higher proportion of all preventable cases are estimated for using PCV20 vs PPV23

324 relative to a scenario without vaccination in Brazil (61·3%, 42·7-89·2) vs (30·1%, 20·6-43·5),

325 Malawi (64·5 %, 13·0-92·2) vs (28·5%, 5·7-73·3), and South Africa (53·1%, 39·7-73·2) vs

326 (19·8%, 13·0-29·2) among adults aged 55y, and in England (27·2%, 21·6-34·5) vs (13·6%, 10·4-

327 17·6) among adults aged 70y, respectively (Table S2). Furthermore, higher proportion of IPD

328 cases are preventable under slow vs rapid waning of PPV23 VE among adults aged 55y in Brazil

329 (40·7%, 29·0-57·1) vs (30·1%, 20·6-43·5), Malawi (38·6 %, 8·0-77·2) vs (28·5%, 5·7-73·3), South

330 Africa (26·4%, 18·2-38·3) vs (19·8%, 13·0-29·2), and among adults aged 70y in England (17·5%,

331 13·8-22·0) vs (13·6%, 10·4-17·6), respectively (Table S3).

It is made available under a CC-BY 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2022.11.07.22282045;](https://doi.org/10.1101/2022.11.07.22282045) this version posted November 8, 2022. The copyright holder for this preprint



333 Figure 2. The impact of routine pneumococcal vaccination in older adults aged  $\geq$ 55 years old (y). 334 The expected absolute number of total IPD cases averted for the rest of age cohort lifetime by 335 vaccinating every older adult in the age cohort stratified by country and vaccine product, under 336 the scenario of age-independent initial vaccine efficacy/effectiveness (VE) and waning VE in 337 Brazil, England, Malawi and South Africa. The lines represent cohort model mean estimates and 338 the shaded ribbon represents 95% bootstrap confidence intervals for the mean estimates. The X 339 corresponds to the optimal age for pneumococcal vaccination. In Brazil, Malawi and South 340 Africa, most cases are preventable at age 55y whereas in England this is achieved at age 70y. 341 /).<br>d<br>:al

342 The optimal age for vaccinating the lowest number of individuals with single dose pneumococcal 343 vaccine to prevent a reported case of IPD (vaccination efficiency) is estimated to differ by 344 country, vaccine product or waning VE assumption (Fig 3). In a base case scenario with rapid 345 waning of PPV23 VE, optimal age for vaccination efficiency is achieved through vaccination at

It is made available under a CC-BY 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2022.11.07.22282045;](https://doi.org/10.1101/2022.11.07.22282045) this version posted November 8, 2022. The copyright holder for this preprint

- 346 60y in Malawi 684 (244-2,009), 65y in Brazil 10,283 (8,165-13,162), and 75y in South Africa
- 347 3,643 (3,004-4,555) and at 80y in England 352 (287-438) (Table S4).





349 Figure 3. The efficiency of routine pneumococcal vaccination in older adults aged ≥55 years old 350 (y). The number of individuals needed to vaccinate to prevent a case in each age of vaccination, 351 stratified by country and vaccine product, under assumptions of age-independent initial vaccine 352 efficacy/effectiveness (VE) and waning VE in Brazil, England, Malawi and South Africa. The 353 lines represent cohort model mean estimates and the shaded ribbon represents 95% bootstrap 354 confidence intervals for the mean estimates. The X represents the optimal age for efficiency of 355 pneumococcal vaccination. Efficiency of vaccination varies by waning VE assumption and 356 country reflecting sensitivity in reported invasive pneumococcal disease cases.

357

358 **Sensitivity analyses** 

359 If a scenario of age-dependent initial VE is considered in a sensitivity analysis, vaccine impact 360 (total cases averted) remains maximum at 55y in Brazil, Malawi, and South Africa irrespective 361 of vaccine product and assumption of waning VE as was the case with the base case scenario of 362 age-independent initial VE. In contrast, optimal age for vaccination drops to 60y in England (Fig 363 S6). In this scenario, the optimal age of vaccination efficiency is achieved by vaccination of 60y 364 in Brazil, Malawi and South Africa, irrespective of vaccine product or assumptions of waning 365 VE. In England, efficiency is achieved in 60y age cohort for PCV20 and PPV23 irrespective of 366 waning VE assumption, and in 80y or 85y for PCV13's and PCV15's slow or fast waning VE, 367 respectively (Fig S7).

# 369 **Discussion**

370 We have assessed the optimal age-targeting for a single-dose PCV/PPV vaccination against VT-371 IPD in older adults ≥55y in Brazil, England, Malawi, and South Africa and find that vaccinating 372 at 55y in considered LIC/MICs maximises preventable burden of IPD while vaccination at 70y is 373 optimal in England. These findings suggest that the optimal age for vaccination may differ 374 between countries and is driven by population age demographic, age-dependent IPD incidence 375 and VE. Our findings were robust across pneumococcal vaccine products, and to alternative 376 assumption on waning of VE. 377 378 The increasing incidence of IPD in older adulthood is outweighed by many more individuals in 379 the fifties in LIC/MICs. The different age population structure in England, with a higher 380 proportion of ≥55y in the middle to older adult ages, results in the optimal age for vaccination 381 peaking later at 70y. The optimal age of vaccination in England also aligns with results from an 382 Australian study that explored the role of timeliness in the cost-effectiveness of older adult 383 vaccination and found that most deaths and hospitalisations were prevented if PCV13 was given 384 to 70y, a peak age of prevented burden before dropping in remaining older ages [15]. 385 386 The age with lowest number of individuals needed to vaccinate to prevent a case (optimal age of

387 vaccination efficiency) differed by country, vaccine product or assumption of waning VE, in part 388 reflecting the differences in sensitivity of IPD surveillance and the complex interplay between 389 different factors influencing vaccination efficiency. Although this finding accounts for life 390 expectancy, it does not consider quality-adjusted life-years losses due to IPD which could shift

391 the optimal age of vaccination efficiency downwards because more individuals affected by IPD 392 would be added to the fifties than elderly.

393

394 Our cohort model prediction of more preventable cases in all settings with the use of PCV20 vs 395 PPV23 under similar conditions reflects higher efficacy/effectiveness of PCV20 than PPV23 [2]. 396 Moreover, a larger number of IPD preventable cases by PCV20 than lesser-valent PCVs 397 underlines the importance of additional serotypes 8, 10A, 11A, 12F and 15B and/or 22F, 33F 398 covered by PCV20 in the remaining IPD burden in the mature infant-PCV era [10]. Generally, 399 other disease endpoints including non-bacteraemic pneumonia may also be important for vaccine 400 choice e.g., PCV13 is shown to be more efficacious in preventing VT non-bacteraemic 401 pneumonia than PPV23 (46% vs 21%) [2], and if included in this analysis, it may likely heighten 402 PCV13 impact to similar levels or higher than PPV23 in England, albeit with higher vaccine 403 cost. With the likely upcoming use of PCV15 and PCV20 in infants in the near future [39], the 404 vaccine preventable fraction of adult disease is likely to diminish correspondingly because of the 405 indirect effects of such infant programme, and thus reducing the benefit of adult programmes 406 that target the same serotypes as those targeted in infants. On the other hand, PCV21 targets most 407 serotypes not targeted by PPV23 or PCV20 [40], which could likely improve tackling the 408 remaining burden of pneumococcal disease in older adults, in the long absence of vaccines that 409 target surface proteins common to all serotypes [41]. However, for LICs/MICs, PCV15, PCV20 410 and PCV21 may likely not be accessible soon due to their high initial costs. 411

412 Of note, we excluded older adults with HIV because they typically are considered separately for 413 pneumococcal vaccination because of their high risk of disease before they reach old age.

414 However, inclusion of older adults with HIV may likely elevate IPD burden in early older 415 adulthood because of their huge presence in early than late adulthood due to survival bias 416 thereby re-enforcing vaccinating early in older adulthood, particularly in Malawi and South 417 Africa where adult HIV prevalence is relatively high [29]. In this analysis, the contribution of 418 PCVs' indirect protection from older adults to overall vaccine impact is ignored because older 419 adults have low carriage rates unlike children who are the main transmitters, and the use of 420 PPV23 does not protect against carriage and therefore unlikely to generate substantial herd 421 immunity [42]. Sequential dosing of vaccine regimens was not modelled, although PCV15 422 followed by PPV23 is now recommended by the advisory committee on immunisation practices 423 (ACIP) in the United States [43]. This sequential regimen would likely generate higher impact 424 than a single dose of PCV20 or PPV23, albeit with cost-effectiveness implications that need 425 further research, particularly in LICs [2].

426

427 PCVs and PPV23 are reported to have limited efficacy/effectiveness against serotype 3 428 pneumococcal carriage and disease [44], and our inclusion of serotype 3 IPD cases in this 429 analysis imply that our vaccine impact estimates are likely biased upwards. PPV23 is already in 430 use in ≥65y in England [17], and we show in this analysis that the effects of PPV23 use have 431 reduced the original IPD burden (Fig 1), and without adjusting for the current PPV23 vaccination 432 programme, our optimal age for vaccination in this country may be overestimated. Reported IPD 433 case data in LMICs are usually incomplete or under-ascertained due to limited resources e.g. 434 only 19 IPD cases were reported in Malawi and even less so when stratified by age and serotype 435 [3]. Thus, our results should be cautiously interpreted. Despite potential biases of case 436 underreporting, it seems reasonable to assume that underreporting is consistent across adult age

- 437 groups, such that a relative change in IPD incidence by age to identify optimal age-targeting 438 vaccination is less likely affected.
- 439
- 440 In conclusion, the optimal age-targeting for vaccination is largely driven by population age
- 441 demographic, age-dependent IPD incidence and VE. In contrast to the typical use in adults in
- 442 HICs, we find that pneumococcal vaccination in 55y older adults in LIC/MICs may be the most
- 443 effective strategy in reducing the IPD burden among older adults without HIV, although
- 444 affordability, cost-effectiveness and infant vaccination plans will also need to considered when
- 445 designing a strategy to protect older adults against pneumococcal disease.

### 447 **Acknowledgements**

- 448 We thank all the individuals working in respective invasive pneumococcal disease (IPD)
- 449 surveillance and laboratory management teams in the four countries for providing important data
- 450 on IPD isolates and related causing serotypes. DT, KCJ, SF NF, RSH, and TDS are supported by
- 451 the National Institute for Health Research (NIHR) Global Health Research Unit on Mucosal
- 452 Pathogens (MPRU) where RSH is a NIHR Senior Investigator. In addition, SF is supported by a
- 453 Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society. We
- 454 would like to thank Stephen Gordon of Liverpool School of Tropical Medicine for insightful
- 455 discussion and feedback at the initial stage of this work.
- 456

### 457 **Author contributions**

- 458 Conceptualization; DT, SC, SF, EM, PM, NA.
- 459 Data curation; DT, JK, SM, TDS, ZAC, NFY, SCGA, MCdCB.
- 460 Formal analysis; DT, SC, SF.
- 461 Funding acquisition; DT, NF, SL, RSH, CC, MCdCB, SF.
- 462 Investigation; DT, SC, JK, AvG, SW, SM, TDS, EM, PM, NA, ZAC, NFY, KJ, NF, SCGA, SL,
- 463 RSH, CC, MCdCB, SF.
- 464 Methodology; DT, SC, NF, SL, RSH, CC, MCdCB, SF
- 465 Project administration; JK, AvG, SW, SM, TDS, ZAC, NFY, KJ, NF, SCGA, SL, RSH, CC,
- 466 MCdCB.
- 467 Resources; DT, NF, SL, RSH, CC, MCdCB, SF.
- 468 Software; DT, SC.
- 469 Supervision; SF, NF

- 470 Validation; SC, JK, AvG, SW, SM, TDS, EM, PM, NA, ZAC, NFY, KJ, NF, SCGA, SL, RSH,
- 471 CC, MCdCB, SF.
- 472 Visualization; DT, SC.
- 473 Writing original draft; DT, SC, SF.
- 474 Writing review & editing; DT, SC, JK, AvG, SW, SM, TDS, EM, PM, NA, ZAC, NFY, KJ,
- 475 NF, SCGA, SL, RSH, CC, MCdCB, SF.
- 476 All authors read and approved the final manuscript.
- 477

#### 478 **Data availability**

- 479 An R script that was used to analyse the datasets and aggregated data are available in the GitHub
- 480 repository https://github.com/deusthindwa/optimal.age.targeting.pneumo.vaccines.
- 481

#### 482 **Declaration of interests**

- 483 The authors declare no competing interests.
- 484

#### 485 **Role of the funding source**

486 A project grant from the National Institute for Health and Care Research (NIHR) Global Health

- 487 Research Unit on Mucosal Pathogens (MPRU) is supported using UK aid from the UK
- 488 Government (Grant 16/136/46). The views expressed in this publication are those of the
- 489 author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.
- 490 The MLW Clinical Research Programme is supported by a Strategic Award from the Wellcome,
- 491 UK. This research was funded in whole, or in part, by the Wellcome Trust [Grant number
- 492 208812/Z/17/Z]. For the purpose of open access, the author has applied a CC BY public

- 493 copyright licence to any Author Accepted Manuscript version arising from this submission. The
- 494 funders had no role in study design, collection, analysis, data interpretation, writing of the report
- 495 or in the decision to submit the paper for publication. The corresponding author and senior
- 496 authors had full access to the study data, and together, had final responsibility for the decision to
- 497 submit for publication

### 499 **References**

- 500 1. Wahl B, O'Brien KL, Greenbaum A, Majumder A, Liu L, Chu Y, et al. Burden of 501 Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era 502 of conjugate vaccines: global, regional, and national estimates for 2000–15. Lancet Glob 503 Health. 2018;6: e744–e757. doi:10.1016/S2214-109X(18)30247-X
- 504 2. Department of Immunization, Vaccines and Biologicals. WHO | SAGE Yellow Book for 505 October 2020 [Internet]. Geneva, Switzerland: WHO; 2020 Oct p. 20. Available: 506 http://www.who.int/immunization/sage/meetings/2020/october/presentations\_background\_ 507 docs/en/
- 508 3. Deloria Knoll M, Bennett JC, Garcia Quesada M, Kagucia EW, Peterson ME, Feikin DR, et 509 al. Global Landscape Review of Serotype-Specific Invasive Pneumococcal Disease 510 Surveillance among Countries Using PCV10/13: The Pneumococcal Serotype Replacement 511 and Distribution Estimation (PSERENADE) Project. Microorganisms. Multidisciplinary 512 Digital Publishing Institute; 2021;9: 742. doi:10.3390/microorganisms9040742
- 513 4. Bonnave C, Mertens D, Peetermans W, Cobbaert K, Ghesquiere B, Deschodt M, et al. 514 Adult vaccination for pneumococcal disease: a comparison of the national guidelines in 515 Europe. Eur J Clin Microbiol Infect Dis. 2019;38: 785–791. doi:10.1007/s10096-019- 516 03485-3
- 517 5. Hurley D, Griffin C, Young M, Scott DA, Pride MW, Scully IL, et al. Safety, Tolerability, 518 and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 519 60 to 64 Years of Age. Clin Infect Dis. doi:10.1093/cid/ciaa1045
- 520 6. CDC Advisory Committee on Immunization Practices (ACIP). EtR for PCV15 use among 521 adults ≥65 years old | CDC [Internet]. 27 Jan 2022 [cited 8 Feb 2022]. Available:<br>522 https://www.cdc.gov/vaccines/acip/recs/grade/pneumo-PCV15-PPSV23-age-base 522 https://www.cdc.gov/vaccines/acip/recs/grade/pneumo-PCV15-PPSV23-age-based-etr.html
- 523 7. Flasche S, Hoek AJV, Goldblatt D, Edmunds WJ, O'Brien KL, Scott JAG, et al. The 524 Potential for Reducing the Number of Pneumococcal Conjugate Vaccine Doses While 525 Sustaining Herd Immunity in High-Income Countries. PLOS Med. 2015;12: e1001839. 526 doi:10.1371/journal.pmed.1001839
- 527 8. von Gottberg A, de Gouveia L, Tempia S, Quan V, Meiring S, von Mollendorf C, et al. 528 Effects of Vaccination on Invasive Pneumococcal Disease in South Africa. N Engl J Med. 529 2014;371: 1889–1899. doi:10.1056/NEJMoa1401914
- 530 9. Bar-Zeev N, Swarthout TD, Everett DB, Alaerts M, Msefula J, Brown C, et al. Impact and 531 effectiveness of 13-valent pneumococcal conjugate vaccine on population incidence of 532 vaccine and non-vaccine serotype invasive pneumococcal disease in Blantyre, Malawi, 533 2006–18: prospective observational time-series and case-control studies. Lancet Glob 534 Health. Elsevier; 2021;9: e989–e998. doi:10.1016/S2214-109X(21)00165-0
- 535 10. Garcia Quesada M, Yang Y, Bennett JC, Hayford K, Zeger SL, Feikin DR, et al. Serotype 536 Distribution of Remaining Pneumococcal Meningitis in the Mature PCV10/13 Period:







- 651 41. Weinberger DM, Harboe ZB, Shapiro ED. Developing Better Pneumococcal Vaccines for 652 Adults. JAMA Intern Med. 2017;177: 303–304. doi:10.1001/jamainternmed.2016.8289 653 42. Flasche S, Lipsitch M, Ojal J, Pinsent A. Estimating the contribution of different age strata 654 to vaccine serotype pneumococcal transmission in the pre vaccine era: a modelling study. 655 BMC Med. 2020;18: 129. doi:10.1186/s12916-020-01601-1 656 43. Kobayashi M. Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent 657 Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the 658 Advisory Committee on Immunization Practices — United States, 2022. MMWR Morb 659 Mortal Wkly Rep. 2022;71. doi:10.15585/mmwr.mm7104a1
- 660 44. Linley E, Bell A, Gritzfeld JF, Borrow R. Should Pneumococcal Serotype 3 Be Included in 661 Serotype-Specific Immunoassays? Vaccines. Multidisciplinary Digital Publishing Institute; 662 2019;7: 4. doi:10.3390/vaccines7010004